Literature DB >> 3199673

Metabolism of complement factor D in renal failure.

M Pascual1, G Steiger, J Estreicher, K Macon, J E Volanakis, J A Schifferli.   

Abstract

Factor D is an essential enzyme of the alternative pathway of complement. Its plasma concentration increases approximately tenfold in end-stage renal failure (ESRF). To analyze its metabolism in humans, we injected purified radiolabelled factor D into 5 healthy individuals and 12 patients with various renal diseases or renal failure. Fractional metabolic rates (FMR) and extravascular/intravascular distributions (EV/IV) were calculated using a compartmental model. The FMR was very rapid in normal individuals (mean 59.6%/hr; range 74.1 to 50.5), significantly diminished in the five patients with ESRF (5.7%/hr; 7.0 to 2.8; P less than 0.004), and correlated well with the creatinine clearance (r = 0.89; P less than 0.001). The extrarenal catabolic rate was not modified in renal failure. Despite a significant inverse correlation between plasma levels of factor D and creatinine clearance [r = 0.68; P less than 0.002], factor D levels were not a sensitive indicator of renal function because the synthesis rate (SR) varied widely from one individual to another (mean SR: 62.9 micrograms/kg/hr; 14.9 to 136.5). Factor D synthesis was not significantly altered by renal function, and did not correlate with C-reactive protein, suggesting that factor D is not an acute phase protein. The proportion of intact factor D elimination in the urine was increased in patients with tubular dysfunction (up to 15% compared to less than 0.2% in normal individuals) confirming that under normal circumstances factor D is filtered through the glomerulus and catabolized by tubular cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3199673     DOI: 10.1038/ki.1988.214

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

Review 1.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

2.  Altered Expression Pattern of CD55 and CD59 on Red Blood Cells in Anemia of Chronic Kidney Disease.

Authors:  Lama Al-Faris; Salah Al-Humood; Fatma Behbehani; Husam Sallam
Journal:  Med Princ Pract       Date:  2017-09-28       Impact factor: 1.927

Review 3.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

Review 4.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

5.  A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects.

Authors:  Baohai Shao; Ian de Boer; Chongren Tang; Philip S Mayer; Leila Zelnick; Maryam Afkarian; Jay W Heinecke; Jonathan Himmelfarb
Journal:  J Proteome Res       Date:  2015-06-15       Impact factor: 4.466

6.  A zebrafish model for uremic toxicity: role of the complement pathway.

Authors:  Nathaniel Berman; Melisa Lectura; Josh Thurman; James Reinecke; Amanda C Raff; Michal L Melamed; James Reinecke; Zhe Quan; Todd Evans; Timothy W Meyer; Thomas H Hostetter
Journal:  Blood Purif       Date:  2013-05-08       Impact factor: 2.614

7.  Complement factor D in age-related macular degeneration.

Authors:  Chloe M Stanton; John R W Yates; Anneke I den Hollander; Johanna M Seddon; Anand Swaroop; Dwight Stambolian; Sascha Fauser; Carel Hoyng; Yi Yu; Kanda Atsuhiro; Kari Branham; Mohammad Othman; Wei Chen; Elod Kortvely; Kevin Chalmers; Caroline Hayward; Anthony T Moore; Baljean Dhillon; Marius Ueffing; Alan F Wright
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-11       Impact factor: 4.799

8.  Identification of Novel Biomarker for Early Detection of Diabetic Nephropathy.

Authors:  Kyeong-Seok Kim; Jin-Sol Lee; Jae-Hyeon Park; Eun-Young Lee; Jong-Seok Moon; Sang-Kyu Lee; Jong-Sil Lee; Jung-Hwan Kim; Hyung-Sik Kim
Journal:  Biomedicines       Date:  2021-04-22

9.  Aptamer-based multiplexed proteomic technology for biomarker discovery.

Authors:  Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N Brody; Jeff Carter; Andrew B Dalby; Bruce E Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R Keeney; Nancy Kim; Tad H Koch; Stephan Kraemer; Luke Kroiss; Ngan Le; Daniel Levine; Wes Lindsey; Bridget Lollo; Wes Mayfield; Mike Mehan; Robert Mehler; Sally K Nelson; Michele Nelson; Dan Nieuwlandt; Malti Nikrad; Urs Ochsner; Rachel M Ostroff; Matt Otis; Thomas Parker; Steve Pietrasiewicz; Daniel I Resnicow; John Rohloff; Glenn Sanders; Sarah Sattin; Daniel Schneider; Britta Singer; Martin Stanton; Alana Sterkel; Alex Stewart; Suzanne Stratford; Jonathan D Vaught; Mike Vrkljan; Jeffrey J Walker; Mike Watrobka; Sheela Waugh; Allison Weiss; Sheri K Wilcox; Alexey Wolfson; Steven K Wolk; Chi Zhang; Dom Zichi
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

10.  Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy.

Authors:  K N Le; L Gibiansky; M van Lookeren Campagne; J Good; T Davancaze; K M Loyet; A Morimoto; E C Strauss; J Y Jin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.